Cardiovascular Risk Management Unmet Needs

The 2 corporations formed the Bristol Myers Squibb-Pfizer Alliance and will be offering discounted Eliquis to eligible patients starting September 8, 2025.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

The Cut Hypertension Program operates in barbershops across the Bay Area in California. The program’s lead pharmacist joined us to discuss main themes and goals of the new initiative.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.